Should the European Medicines Agency consider ageing a disease?
The classification of ageing as a disease is fundamental to developing new pharmacological strategies that can target said phenomenon. The European Medicines Agency does not do this and maintains a questionable perspective based on the traditional naturalistic argument and the value-free ideal. An a...
Main Author: | |
---|---|
Format: | Electronic Article |
Language: | English |
Check availability: | HBZ Gateway |
Journals Online & Print: | |
Fernleihe: | Fernleihe für die Fachinformationsdienste |
Published: |
Wiley-Blackwell
2024
|
In: |
Bioethics
Year: 2024, Volume: 38, Issue: 5, Pages: 431-437 |
IxTheo Classification: | KBA Western Europe NBE Anthropology NCH Medical ethics |
Further subjects: | B
LIFESPAN
B antiageing medicines B Ageing B Longevity B European Medicines Agency |
Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |
MARC
LEADER | 00000caa a22000002 4500 | ||
---|---|---|---|
001 | 1888089091 | ||
003 | DE-627 | ||
005 | 20240613081325.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240508s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/bioe.13265 |2 doi | |
035 | |a (DE-627)1888089091 | ||
035 | |a (DE-599)KXP1888089091 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
084 | |a 1 |2 ssgn | ||
100 | 1 | |a Marín Penella, Guillermo |e VerfasserIn |4 aut | |
245 | 1 | 0 | |a Should the European Medicines Agency consider ageing a disease? |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The classification of ageing as a disease is fundamental to developing new pharmacological strategies that can target said phenomenon. The European Medicines Agency does not do this and maintains a questionable perspective based on the traditional naturalistic argument and the value-free ideal. An alternative is proposed which, inspired by consequentialism, is committed to considering ageing as a disease in European regulatory contexts as long as the ethical consequences are desirable. Within a realistic framework, I show that making this decision would have moderate positive effects such as increased knowledge about antiageing pharmacology or potential greater chances of completing vital projects. Furthermore, we will see that the main arguments used by critics to show that the negative effects outweigh the positive ones are not sound. Therefore, I conclude that it would be beneficial for the European Medicines Agency to change its position on ageing. | ||
650 | 4 | |a Longevity | |
650 | 4 | |a LIFESPAN | |
650 | 4 | |a European Medicines Agency | |
650 | 4 | |a antiageing medicines | |
650 | 4 | |a Ageing | |
652 | |a KBA:NBE:NCH | ||
773 | 0 | 8 | |i Enthalten in |t Bioethics |d Oxford [u.a.] : Wiley-Blackwell, 1987 |g 38(2024), 5, Seite 431-437 |h Online-Ressource |w (DE-627)271596708 |w (DE-600)1480658-7 |w (DE-576)078707986 |x 1467-8519 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2024 |g number:5 |g pages:431-437 |
856 | |u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bioe.13265 |x unpaywall |z Vermutlich kostenfreier Zugang |h publisher [open (via crossref license)] | ||
856 | 4 | 0 | |u https://doi.org/10.1111/bioe.13265 |x Resolving-System |z kostenfrei |3 Volltext |
856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.13265 |x Verlag |z kostenfrei |3 Volltext |
912 | |a NOMM | ||
935 | |a mteo | ||
951 | |a AR | ||
ELC | |a 1 | ||
ITA | |a 1 |t 1 | ||
LOK | |0 000 xxxxxcx a22 zn 4500 | ||
LOK | |0 001 4521483925 | ||
LOK | |0 003 DE-627 | ||
LOK | |0 004 1888089091 | ||
LOK | |0 005 20240702144853 | ||
LOK | |0 008 240508||||||||||||||||ger||||||| | ||
LOK | |0 035 |a (DE-Tue135)IxTheo#2024-05-07#3068F1FA666DE24A5095749A3765239BC4D28393 | ||
LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
LOK | |0 092 |o n | ||
LOK | |0 852 |a DE-Tue135 | ||
LOK | |0 852 1 |9 00 | ||
LOK | |0 935 |a ixzs |a zota | ||
LOK | |0 936ln |0 144205168X |a NBE | ||
LOK | |0 936ln |0 1550736558 |a NCH | ||
LOK | |0 936ln |0 1442044691 |a KBA | ||
OAS | |a 1 | ||
ORI | |a SA-MARC-ixtheoa001.raw |